Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of February 28, 2026, Kiniksa Pharmaceuticals, Ltd. (KNSA) has a Wall Street consensus price target of $55.67, based on estimates from 10 covering analysts. With the stock currently trading at $44.49, this represents a potential upside of +25.1%. The company has a market capitalization of $3.39B.
Analyst price targets range from a low of $50.00 to a high of $62.00, representing a 22% spread in expectations. The median target of $55.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 10 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, KNSA trades at a trailing P/E of 59.3x and forward P/E of 34.8x. Analysts expect EPS to grow -14.9% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $418.73, with bear and bull scenarios of $-13871.18 and $448.43 respectively. Model confidence stands at 26/100, suggesting limited visibility into future performance.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how KNSA stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for KNSA is $55.67, representing 25.1% upside from the current price of $44.49. With 10 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
KNSA has a consensus rating of "Buy" based on 10 Wall Street analysts. The rating breakdown is predominantly bullish, with 10 Buy/Strong Buy ratings. The consensus 12-month price target of $55.67 implies 25.1% upside from current levels.
KNSA trades at a forward P/E of 34.785x, representing a moderate valuation. With analysts targeting $55.67 (25.1% implied move), the stock appears reasonably valued with upside.
The most bullish Wall Street analyst has a price target of $62 for KNSA, while the most conservative target is $50. The consensus of $55.67 represents the median expectation. Our quantitative valuation model projects a bull case target of $448 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
KNSA is moderately covered, with 10 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 10 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month KNSA stock forecast based on 10 Wall Street analysts shows a consensus price target of $55.67, with estimates ranging from $50 (bear case) to $62 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $419, with bear/bull scenarios of $-13871/$448.
Our quantitative valuation model calculates KNSA's fair value at $419 (base case), with a bear case of $-13871 and bull case of $448. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 26/100.
KNSA trades at a forward P/E ratio of 34.8x based on next-twelve-months earnings estimates compared to a trailing P/E of 59.3x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on KNSA, with a "Buy" consensus rating and $55.67 price target (25.1% upside). 10 of 10 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
KNSA analyst price targets range from $50 to $62, a 22% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $55.67 consensus represents the middle ground. Our model's $-13871-$448 range provides an independent fundamental perspective.